Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3277510A and GSK3277509A in Adults 18 to 60 Years of Age

Summary

The purpose of this study is to evaluate the safety and immunogenicity of different formulations of GSK Biologicals' H7N9 influenza vaccine in subjects 18 to 60 years of age.

Timeline

Start

2016-03

Primary completion

2016-06

Completion

2017-05

Outcome

Outcome not reported

Stopped: “The study was cancelled for scientifically legitimate reasons not related to safety or efficacy of the vaccine.”

Drugs

Indications